Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (IBV). The methods typically include passing a heterogeneous attenuated population of IBV in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of IBV in embryonated chicken eggs (ECE) in order to obtain passaged attenuated population of IBV. Also disclosed are passaged attenuated populations of IBV in which the populations display a desired degree of homogeneity. Also disclosed are vaccines comprising the passaged attenuated populations of IBV and methods of vaccination comprising administering the disclosed vaccines.

Disclosed are methods for preparing a vaccine against infection by infectious bronchitis virus (IBV). The methods typically include passing a heterogeneous attenuated population of IBV in chicken embryonic kidney cells, and optionally may include further passaging the heterogeneous attenuated population of IBV in embryonated chicken eggs (ECE) in order to obtain passaged attenuated population of IBV. Also disclosed are passaged attenuated populations of IBV in which the populations display a desired degree of homogeneity. Also disclosed are vaccines comprising the passaged attenuated populations of IBV and methods of vaccination comprising administering the disclosed vaccines.

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The present disclosure provides recombinantly manufactured fusion proteins comprising a SARS-CoV-2 Receptor Binding Domain (SARS-CoV-2-RBD) fragment or an analog thereof linked to a human Fc fragment for use in relation to the 2019 Novel Coronavirus (COVID-19). Embodiments include the administration of the fusion proteins to patients that have recovered from COVID-19 as a booster vaccination, to antibody naïve patients to produce antibodies to the SARS-CoV-2 virus to enable the patients to become convalescent plasma donors, to patients who have been infected by the SARS-CoV-2 virus and have contracted COVID-19 in order to limit the scope of the infection and ameliorate the disease, and as a prophylactic COVID-19 vaccine. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

Betacoronavirus Spike proteins, or fragments thereof, including substitution mutations designed to increase stability, decrease the risk of antibody dependent enhancement, or both; and that are useful in, for example, immunogenic compositions.

Betacoronavirus Spike proteins, or fragments thereof, including substitution mutations designed to increase stability, decrease the risk of antibody dependent enhancement, or both; and that are useful in, for example, immunogenic compositions.

The present disclosure relates to recombinant human adenoviruses engineered to express a structural protein of a coronavirus. The recombinant adenoviruses are suitable for active immunization against a coronavirus in a human subject. Additionally, immune globulin obtained from immunized human subjects is suitable for passive immunization of a coronavirus-infected human subject.

The present disclosure relates to recombinant human adenoviruses engineered to express a structural protein of a coronavirus. The recombinant adenoviruses are suitable for active immunization against a coronavirus in a human subject. Additionally, immune globulin obtained from immunized human subjects is suitable for passive immunization of a coronavirus-infected human subject.

Compositions and methods for the prevention and/or treatment of SARS-CoV-2 infection and/or COVID-19 are described.

The invention relates to methods for modulating the neurological and immune function through targeting of acetylcholine (ACh) and CLIP. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including psychiatric or neurological disease, autoimmune disease, transplant and cell graft rejection, chronic wounds, non-neuronal immune disorders, Alzheimer's, Parkinson's Disease, Lewy Body dementia, pediatric acute neuropsychiatric syndromes (PANS), hypertension, late stage Ebola, Hantavirus, or coronavirus-induced hyperinflammatory conditions, including infections that cause a pathological “cytokine storm”, other post-infectious syndromes that result in cytokine storms in some people, and cancer, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject and improving cognition and addiction cessation methods. In some embodiments the addiction is an addiction to smoking, alcohol and/or drugs.